Edward Skolnik, MD

In the final episode, Near-Term Priorities for Transforming Clinical Practice in IgA Nephropathy, the panelist explored the following critical question: What do you hope to see in the next 1–2 years in terms of clinical practice change?

This episode, titled Rethinking KDIGO Guidance and Payer Models in the Era of Targeted IgA Nephropathy Therapies, features expert nephrologists discussing the following critical questions: What updates to KDIGO will likely need to be made in view of these novel therapies being approved? How should payers and health systems think differently about treating this disease?

In Advocacy Strategies and the Expanding Role of Novel Therapies in IgA Nephropathy, our panel delves into the following critical questions: What strategies can clinicians use to advocate for access or navigate step edits? How might real-world data and ongoing registries (like RaDaR) support broader adoption and payer confidence?

In this episode, Overcoming Access Barriers and Step-Edit Challenges in IgA Nephropathy Care, the panelists explore the following questions: What barriers exist to real-world use, particularly around payer policies or access? Many plans require a systemic steroid step-edit; why might this be inappropriate for IgAN?